PharmAust

📢 Join PharmAust at Australia’s Largest Investment Conference for the Tech Sector – the TechKnow Invest Roadshow! This premier event will feature ASX-listed tech & medtech companies and provides an ideal environment for investors and brokers to connect and hear from industry leaders. 📅 Dates & Locations: Swissôtel Sydney: 30 July 2024 Rydges Melbourne: 31 July 2024 For more information on the conference and how to participate, visit: https://lnkd.in/gxMi84Db See you there! #TechKnow2024 #PharmAust #MedTech #InvestmentConference #ASX

We are thrilled to announce that our Managing Director and CEO, Dr. Michael Thurn, was featured on the "Let's Talk MND" podcast hosted by Jane Simpson! 🎙️ In this episode, Dr. Thurn shares insights on PharmAust's innovative efforts to advance Monepantel as a treatment for ALS and MND. Listen to the podcast here: https://lnkd.in/giNh-iXM #Biotechnology #NeurodegenerativeDiseases #Innovation #PharmAust #Leadership #MND #ALS

PharmAust Completes Successful Share Purchase Plan We are thrilled to announce the completion of our Share Purchase Plan (SPP), which raised an impressive $7.8 million, significantly exceeding our initial $2 million target. This strong demand reflects the exceptional support from our shareholders, who were offered the same terms as our recently completed $10 million institutional Placement. The combined $17.8 million from the SPP and Placement substantially strengthens our balance sheet and minimizes future funding needs as we advance the development of monepantel for ALS and other neurodegenerative conditions. Our Chairman, Sergio Duchini, extends his heartfelt gratitude to all shareholders for their unwavering support and confidence in PharmAust’s strategic direction. PharmAust Chairman Sergio Duchini commented: 'With these funds, we are well-positioned to commence the HEALEY ALS Platform Trial and achieve significant milestones in H2 CY2024. We look forward to keeping you updated on our progress." Thank you to all our shareholders for your continued support! #PharmAust #ASX #ALSResearch #NeurodegenerativeDiseases #Biotech #CapitalRaising #SharePurchasePlan

We're thrilled to announce that monepantel has been accepted onto the prestigious HEALEY ALS Platform Trial in the US for its STRIKE2/3 trial! 🌟 This significant partnership with the HEALEY ALS Platform Trial provides invaluable exposure within the ALS research community and marks a crucial step in our efforts to develop monepantel as a viable treatment for ALS. The opportunity to be part of the HEALEY Platform via their extensive US network of clinical sites is substantial. We remain committed to supporting the ALS community in Australia, and ultimately, the HEALEY platform will provide us with the most efficient and safest way to bring monepantel to all patients. This collaboration, with its streamlined regulatory support and engagement with leading ALS experts, is a critical advancement in our mission to offer a much-needed therapy for ALS patients. For more information about the HEALEY ALS Platform Trial, please visit their website. #ALSResearch #PharmAust #Monepantel #HealeyPlatform #ClinicalTrials #NeurologicalDiseases #MedicalResearch

PharmAust awarded SME status in Europe, further promoting MND treatment.

📢 PharmAust Granted SME Status by European Medicines Agency We are thrilled to share that PharmAust has been granted Small and Medium-sized Enterprise (SME) status by the European Medicines Agency (EMA). This recognition provides us with valuable financial incentives, including reduced fees for scientific advice, inspections, and marketing authorisation applications. This milestone will significantly streamline our regulatory engagement and support the advancement of our monepantel (MPL) program for the treatment of Motor Neurone Disease (MND) / Amyotrophic Lateral Sclerosis (ALS). Our Managing Director, Dr. Michael Thurn, expressed pride in this achievement and highlighted the importance of this partnership with the EMA in accelerating the Phase 2/3 STRIKE study. Stay tuned for more updates as we continue our journey to make a difference in the lives of those affected by MND/ALS. #PharmAust #Biotech #MND #ALS #EMA 

🌟 Congratulations to Our Esteemed Phase 1 MEND Study Investigators! 🌟 We are thrilled to announce that Assoc Prof. Susan Mathers and Prof. Dominic Rowe have both received the Lifetime Achievement Award from MND Australia, recognizing their significant contributions to the fight against Motor Neurone Disease (MND) over the last 30 years. Their dedication and groundbreaking work in MND research have not only advanced our understanding but also brought hope to countless patients and families affected by this challenging disease. At PharmAust, we are incredibly proud to be associated with such luminaries in the field of MND research. Their passion and perseverance inspire us every day as we continue our mission to develop innovative treatments for neurodegenerative diseases. Join us in celebrating their remarkable achievements and commitment to making a difference in the world of MND research! #PharmAust #MNDAustralia #MNDResearch #LifetimeAchievement #HealthcareHeroes

Today at Parliament House, MND Australia and FightMND came together for the MND Australia Global Day Event. Our executives joined forces to raise awareness and show support for those living with Motor Neurone Disease. It’s inspiring to see such dedication to a crucial cause. Let’s continue to spread the word and support the fight against MND. 💙 #MNDAustralia #FightMND #MNDGlobalDay

Stockhead’s Break it Down brings you today’s leading market news in under 90 seconds. https://buff.ly/4cyYKwB #ASX PharmAust

Exciting news for our investors! 🎉 We invite you to explore the details of our latest capital raise here: https://lnkd.in/gkmZxQNz. We are delighted with the support from our existing shareholders and welcome new shareholders to our register. This capital raise is a vote of confidence in the exciting opportunity ahead for us with monepantel, along with the quality of our people and our strategy. Thank you for your continued support as we move forward together! 🌟 #PharmAust #InvestorUpdate #CapitalRaise #ALS